BTIG Reiterates a Hold Rating on Varian Medical SystemsBy Carrie Williams
According to TipRanks.com, Lavin is a top 100 analyst with an average return of 12.5% and a 63.9% success rate. Lavin covers the Healthcare sector, focusing on stocks such as Tactile Systems Technology, Trivascular Technologies, and Boston Scientific Corp.
Varian Medical Systems has an analyst consensus of Moderate Buy, with a price target consensus of $98.50.
Varian Medical Systems’ market cap is currently $8.5B and has a P/E ratio of 21.45. The company has a book value ratio of 5.0326.
Based on the recent corporate insider activity of 58 insiders, corporate insider sentiment is neutral on the stock. Most recently, in June 2016, Ruediger Naumann-Etienne, a a Director at VAR sold 1,000 shares for a total of $84,830.
Varian Medical Systems, Inc. engages in the manufacture of medical devices and software for treating cancer and other medical condition. It operates through the two segments: Oncology Systems and Imaging Components. The Oncology Systems segment designs, manufactures, sells, and services hardware and software products for treating cancer with conventional radiotherapy including IMRT, IGRT and volumetric modulated arc therapy, stereotactic body radiotherapy, stereotactic radiotherapy, stereotactic radiosurgery and brachytherapy. The Imaging Components segment designs, manufactures, sells, and services X-ray imaging components for use in different applications, including radiographic or fluoroscopic imaging, mammography, specific procedures, computed tomography, and industrial applications. The Other segment comprises of Varian Particle Therapy, which manufactures and sells products and systems for delivering proton therapy; and operations of the Ginzton Technology Center, which is the firm’s scientific research facility. The company was founded by William Hansen, Edward Ginzton, Russell Varian, and Sigurd Varian in 1948 and is headquartered in Palo Alto, CA.